Candesartan cilexetil - Generic Drug Details

What are the generic sources for candesartan cilexetil and what is the scope of freedom to operate?

Candesartan cilexetil is the generic ingredient in four branded drugs marketed by Ani Pharms, Alembic, Apotex, Macleods Pharms Ltd, Mylan, Prinston Inc, Zydus Lifesciences, Apotex Inc, Pharmobedient, and Senores Pharms, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-two drug master file entries for candesartan cilexetil. Ten suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for candesartan cilexetil

US Patents:	0
Tradenames:	4
Applicants:	10
NDAs:	15
Drug Master File Entries:	22
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	68
Patent Applications:	7,658
Drug Prices:	Drug price trends for candesartan cilexetil
What excipients (inactive ingredients) are in candesartan cilexetil?	candesartan cilexetil excipients list
DailyMed Link:	candesartan cilexetil at DailyMed

See drug prices for candesartan cilexetil

Recent Clinical Trials for candesartan cilexetil

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
United States Department of Defense	Phase 2
University of California, San Francisco	Phase 2
The George Institute for Global Health, India	Phase 2

See all candesartan cilexetil clinical trials

Generic filers with tentative approvals for CANDESARTAN CILEXETIL

Applicant	Application No.	Strength	Dosage Form
		32MG; 25MG	TABLET; ORAL
		32MG; 12.5MG	TABLET; ORAL
		16MG; 12.5MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for candesartan cilexetil

Drug Class	Angiotensin 2 Receptor Blocker
Mechanism of Action	Angiotensin 2 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for candesartan cilexetil

C09CA	Angiotensin II receptor blockers (ARBs), plain
C09C	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

Paragraph IV (Patent) Challenges for CANDESARTAN CILEXETIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ATACAND	Tablets	candesartan cilexetil	4 mg, 8 mg, 16 mg and 32 mg	020838	1	2006-12-22

US Patents and Regulatory Information for candesartan cilexetil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	CANDESARTAN CILEXETIL	candesartan cilexetil	TABLET;ORAL	210302-003	Dec 4, 2018	AB	RX	No	No
Zydus Lifesciences	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	203466-002	Nov 27, 2017	AB	RX	No	No
Mylan	CANDESARTAN CILEXETIL	candesartan cilexetil	TABLET;ORAL	078702-002	May 3, 2013	AB	RX	No	No

Expired US Patents for candesartan cilexetil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ani Pharms	ATACAND	candesartan cilexetil	TABLET;ORAL	020838-003	Jun 4, 1998	5,703,110
Ani Pharms	ATACAND	candesartan cilexetil	TABLET;ORAL	020838-004	Jun 4, 1998	5,705,517*PED
Ani Pharms	ATACAND	candesartan cilexetil	TABLET;ORAL	020838-002	Jun 4, 1998	7,538,133*PED

Market Dynamics and Financial Trajectory for Candesartan Cilexetil

Last updated: February 20, 2026

Candesartan cilexetil is a selective angiotensin II receptor blocker (ARB) approved for the management of hypertension and heart failure. Since its market entry, the drug has experienced steady growth, influenced by regulatory developments, competitive landscape shifts, and healthcare trends.

Market Overview

The global antihypertensive drugs market exceeded USD 34 billion in 2022. Candesartan cilexetil contributes a significant segment within ARBs, which accounted for approximately USD 8.2 billion in 2022, with continued growth projected at a Compound Annual Growth Rate (CAGR) of 4.2% through 2030.

Key Market Drivers

• Increased Hypertension Prevalence: Approximately 1.28 billion adults globally have hypertension, driving demand for ARBs.
• Cardiovascular Disease (CVD) Management: Candesartan cilexetil is prescribed for heart failure, post-myocardial infarction, and hypertensive crisis.
• Favorable Side-Effect Profile: Compared to ACE inhibitors, candesartan offers a lower incidence of cough and angioedema, supporting adherence.
• Generic Availability: Patent expirations have led to multiple generic versions, reducing costs and broadening access.
• Line Extensions and Combinations: Fixed-dose combinations (FDCs) with other antihypertensives expand therapeutic options.

Patent and Regulatory Landscape

Candesartan cilexetil's patent expired in many markets by 2015. Generic versions are now available in the US, EU, and emerging economies. Patent protections for some formulations (e.g., specific FDCs) extend until 2024-2026.

Regulatory agencies like the FDA and EMA oversee approvals. Recent guidelines emphasize evidence-based use for hypertensive and heart failure indications, impacting prescribing practices.

Competitive Landscape

Major suppliers include:

• Takeda Pharmaceuticals: Original developer, with a dominant market share prior to patent expiration.
• Generic Manufacturers: Teva, Mylan, Sandoz, and others hold substantial market portions due to cost advantages.
• Combination Product Makers: Firms developing candesartan-based FDCs with amlodipine, hydrochlorothiazide, or other agents.

Market share distribution reflects a shift toward generics, with branded sales declining post-patent expiry.

Financial Trajectory

Revenue Trends

In 2014, candesartan cilexetil-generated sales exceeded USD 1 billion globally. Post-patent loss, branded sales decreased by 45% in the US by 2016, with generics capturing majority market share.

Pricing and Market Penetration

Generic pricing in developed markets has reduced by an average of 60-75% since patent expiry, leading to increased volume sales but decreased per-unit revenue. For instance, in the US, the average retail price for a 30-day supply fell from USD 120 in 2014 to below USD 30 in 2022.

Forecasted Sales

Between 2023 and 2030, global sales are projected to grow from USD 1.2 billion to USD 1.6 billion, driven by rising hypertension prevalence, especially in Asia-Pacific and Latin American markets, where generic penetration remains lower.

Regional Variations

• United States: Market saturation with generics, slower growth.
• Europe: Moderate growth, with increasing adoption of FDCs.
• Emerging Markets: Rapid sales growth, driven by expanding healthcare access and lower drug costs.

External Influences on Market and Financials

• Healthcare Policies: Price controls in Europe and Asia limit revenue growth.
• Reimbursement Policies: Favorability toward generics boosts uptake.
• New Therapeutics: Introduction of novel ARBs and combination therapies (e.g., sacubitril/valsartan) impacts market share.

Risks and Opportunities

Risks:

• Pricing pressure from generics.
• Regulatory delays for new formulations.
• Competition from novel antihypertensives and ARBs.

Opportunities:

• Development of novel formulations (extended-release, FDCs).
• Expansion into emerging markets.
• Potential patent filings for new uses or combinations.

Key Takeaways

• Candesartan cilexetil's revenue declined sharply post-2015 patent expiration, but volume sales compensated partially.
• Generic competition reduces per-unit prices, constraining revenue growth in developed markets.
• Global sales are forecasted to grow modestly (~3% CAGR) due to demographic trends and increasing hypertension diagnoses.
• Emerging markets present growth opportunities due to expanding healthcare infrastructure and affordability.
• Strategic focus on formulation innovation and market expansion can mitigate revenue pressures.

FAQs

1. What has been the impact of patent expiration on candesartan cilexetil revenues?
Patent expiration in 2015 led to widespread generic entry, decreasing branded sales and price points, shifting revenue reliance to volume.

2. How does generic competition influence the global market for candesartan cilexetil?
It reduces prices by 60-75% in mature markets, diminishes branded sales, and encourages wider access but limits profit margins.

3. Are there new formulations or combinations for candesartan cilexetil under development?
Yes. Fixed-dose combinations with amlodipine or hydrochlorothiazide are available, and research into extended-release formulations continues.

4. What regional factors affect the growth trajectory of candesartan cilexetil?
Price controls and reimbursement policies impact mature markets; rising hypertension prevalence and healthcare access drive growth in emerging economies.

5. How might upcoming patents influence the market in the next five years?
New patents for specific formulations or uses could temporarily boost revenues before generic competition increases.

---

References

[1] MarketWatch. (2022). Global antihypertensive drugs market size.
[2] IMS Health. (2014). Cardiovascular drug market data.
[3] European Medicines Agency. (2022). Approved antihypertensive drugs.
[4] FDA. (2020). Guidance on generic drug approval procedures.
[5] IQVIA. (2023). Emerging markets healthcare trends.